FibroGen General and Administrative Expenses 2011-2026 | FGEN

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.

What these expenses include

Salaries of administrative staff (executives, HR, accountants, legal personnel)
Office rent and utilities
Office equipment and IT infrastructure
Professional services (auditors, lawyers, consultants)
Insurance
General administrative travel and representation expenses

What the metric indicates

Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure
Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit
Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry
Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses FibroGen

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
27.7 M	49.3 M	115 M	125 M	124 M	106 M	-	63.8 M	51.8 M	46 M	44.4 M	36.9 M	24.4 M	18.9 M	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
125 M	18.9 M	64.1 M

Quarterly General and Administrative Expenses FibroGen

2025-Q3	2025-Q2	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
5.3 M	7.06 M	-	9.36 M	14.9 M	22.8 M	-	25.6 M	31.2 M	34.3 M	-	29.9 M	30.3 M	30.6 M	-	89.2 M	63.3 M	30.8 M	-	-49 M	63.5 M	49.6 M	-	35.8 M	26.7 M	22.2 M	-	15.4 M	15.1 M	15.6 M	-	13 M	13.4 M	11.5 M	-	11.6 M	10.4 M	11.4 M	-	11.2 M	9.68 M	10.5 M	-	10.1 M	7.52 M	6.43 M	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
89.2 M	-49 M	21.3 M

General and Administrative Expenses of other stocks in the Biotechnology industry

Issuer	General and Administrative Expenses	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	78.3 M	-	2.43 %	$ 254 M	Germany
AgeX Therapeutics AGE	11 M	-	-10.17 %	$ 12.2 K	USA
Aptorum Group Limited APM	5.41 M	$ 0.88	-	$ 6.47 M	China
Aquestive Therapeutics AQST	79.8 M	$ 4.12	0.37 %	$ 441 M	USA
I-Mab IMAB	900 M	-	-	$ 866 M	China
Akero Therapeutics AKRO	37.9 M	-	-	$ 3.67 B	USA
Midatech Pharma plc MTP	4.95 M	-	-18.52 %	$ 27.3 M	Britain
AlloVir ALVR	11 M	-	4.14 %	$ 49.1 M	USA
Alexion Pharmaceuticals, Inc. ALXN	1.4 B	-	-	$ 40.3 B	USA
Biohaven Pharmaceutical Holding Company Ltd. BHVN	714 M	$ 9.7	1.09 %	$ 627 M	USA
Biophytis SA BPTS	7.15 M	-	-13.47 %	$ 169 M	France
Genfit SA GNFT	16.2 M	-	2.54 %	$ 160 B	France
ACADIA Pharmaceuticals ACAD	488 M	$ 21.83	-2.76 %	$ 3.62 B	USA
EyeGate Pharmaceuticals, Inc. EYEG	4.66 M	-	-1.52 %	$ 24.7 M	USA
Athira Pharma ATHA	16.7 M	-	-	$ 269 M	USA
Applied Molecular Transport AMTI	37.4 M	-	-	$ 10.1 M	USA
Ayala Pharmaceuticals AYLA	1.53 M	-	-	$ 7.46 M	Israel
AstraZeneca PLC AZN	15.2 B	-	-	$ 96.9 B	Britain
Burford Capital Limited BUR	99.3 M	$ 5.0	1.42 %	$ 801 M	Britain
Atreca BCEL	31.5 M	-	-11.76 %	$ 5.79 M	USA
Berkeley Lights BLI	95.1 M	-	-7.31 %	$ 87 M	USA
Calithera Biosciences CALA	20.9 M	-	-10.95 %	$ 876 K	USA
Advaxis ADXS	12.2 M	-	-9.65 %	$ 45.9 M	USA
CymaBay Therapeutics CBAY	52 M	-	-	$ 3.45 B	USA
ChemoCentryx CCXI	78.9 M	-	-	$ 3.74 B	USA
Cerus Corporation CERS	80.9 M	$ 2.91	43.35 %	$ 555 M	USA
Институт стволовых клеток человека ISKJ	25.8 M	-	-	-	Russia
Caladrius Biosciences CLBS	12.1 M	-	-16.75 %	$ 25.8 M	USA
Checkmate Pharmaceuticals CMPI	15.7 M	-	-	$ 231 M	USA
Aeterna Zentaris AEZS	5.92 M	-	5.93 %	$ 314 M	Canada
BioNTech SE BNTX	286 M	$ 96.45	-6.77 %	$ 27.2 B	Germany
Brainstorm Cell Therapeutics BCLI	5.78 M	-	-2.5 %	$ 5.88 M	USA
Aeglea BioTherapeutics AGLE	47.9 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	17 M	-	-	$ 26.5 M	USA
Deciphera Pharmaceuticals DCPH	136 M	-	-	$ 2.18 B	USA
AIkido Pharma AIKI	23.8 M	-	1.93 %	$ 17.4 M	USA
Innate Pharma S.A. IPHA	25.5 M	$ 1.44	-	$ 235 M	France
Dynavax Technologies Corporation DVAX	170 M	-	-	$ 2.02 B	USA
Akouos AKUS	22.2 M	-	0.23 %	$ 488 M	USA
Allakos ALLK	45.1 M	-	-	$ 28.6 M	USA
Editas Medicine EDIT	49.9 M	$ 2.9	-3.33 %	$ 257 M	USA
Can-Fite BioPharma Ltd. CANF	3.66 M	$ 3.04	-4.7 %	$ 5 M	Israel
Eiger BioPharmaceuticals EIGR	25.2 M	-	-9.21 %	$ 2.55 M	USA
Edesa Biotech EDSA	4.13 M	$ 18.7	2.33 %	$ 59.8 M	USA
Eloxx Pharmaceuticals ELOX	10.7 M	-	-5.68 %	$ 8.28 M	USA
CureVac N.V. CVAC	100 M	-	-	$ 867 M	Germany
Ampio Pharmaceuticals AMPE	7.08 M	-	-11.43 %	$ 502 K	USA
Evogene Ltd. EVGN	7.25 M	$ 0.78	-0.37 %	$ 27.9 M	Israel
Applied Therapeutics APLT	20.6 M	-	-	$ 8.42 M	USA
Aptose Biosciences APTO	13.4 M	-	-45.71 %	$ 1.2 M	Canada